Login to Your Account



Pharma: Other News To Note


Friday, August 31, 2012
• Abbott, of Abbott Park, Ill., said the European Commission approved Humira (adalimumab) in moderately active Crohn's disease (CD) in adult patients who have not adequately responded to conventional therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription